VANCOUVER, April 2, 2015 /CNW/ - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the
development of autologous cell therapies, today announced that it has
applied to the TSX Venture Exchange to extend the term of 2,043,555
share purchase warrants (the "Warrants"). The original term of
1,643,555 of the Warrants was two years and expires on April 10, 2015
and the original term of 400,000 of the Warrants was two years and
expires on May 21, 2015. The Company proposes to extend the expiry date
for a period of one year to April 10, 2016 for 1,643,555 of the
Warrants and to May 21, 2016 for 400,000 of the Warrants. In all other
respects the terms of the Warrants will remain unchanged and in full
force and effect.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing
autologous cell therapies that address diseases caused by a deficit of
healthy cells required for normal healing and function. The company's
RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic
tendinosis, damaged or aging skin, and pattern baldness. All product
candidates are based on RepliCel's innovative technology utilizing cell
populations isolated from a patient's own healthy hair follicles. The
company is also developing a propriety injection device optimized for
the administration of its products and licensable for use with other
dermatology applications. The company's product pipeline is comprised
of multiple clinical trials anticipated to launch through Q1 2015 in
addition to Shiseido's own clinical trial of RCH-01 and the device in
late prototype development. Visit www.replicel.com for additional information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE RepliCel Life Sciences Inc.
For further information:
Tammey George, Director of Communications
Lee Buckler, VP Business & Corporate Development